Wall Street Zen lowered shares of Organogenesis (NASDAQ:ORGO – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Sunday,Wall Street Zen reports.
Other research analysts also recently issued reports about the company. Truist Financial decreased their price target on Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Weiss Ratings upgraded Organogenesis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Organogenesis presently has a consensus rating of “Reduce” and a consensus target price of $4.33.
Read Our Latest Analysis on Organogenesis
Organogenesis Price Performance
Shares of NASDAQ:ORGO opened at $0.81 on Friday. The company’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $2.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.32 and a quick ratio of 2.76. Organogenesis has a one year low of $0.73 and a one year high of $5.99.
Organogenesis (NASDAQ:ORGO – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $45.46 million during the quarter, compared to the consensus estimate of $52.10 million. Organogenesis had a negative net margin of 39.34% and a negative return on equity of 55.28%.
Institutional Investors Weigh In On Organogenesis
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Organogenesis in the second quarter valued at approximately $17,616,000. Deutsche Bank AG acquired a new stake in shares of Organogenesis in the second quarter valued at approximately $4,146,000. Bank of America Corp DE acquired a new stake in shares of Organogenesis in the second quarter valued at approximately $1,368,000. Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis in the second quarter valued at approximately $37,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Organogenesis during the 2nd quarter worth approximately $44,000. 49.57% of the stock is owned by institutional investors.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
See Also
- Five stocks we like better than Organogenesis
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
